The NObreath device from the British company Bedfont Scientific is a fractional exhaled nitric oxide (FeNO) breath-testing monitor that helps detect and manage inflammatory conditions, COPD and asthma.
According to the company, airway inflammation is a central process in asthma and other lung diseases. Being able to measure this inflammation and monitor the patient’s reaction to medication are “regarded as gold standards in the management of respiratory disease.” The FeNO measurement to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine, but until now it has been an expensive test to deliver in everyday practice.
The NObreath is cost-effective, non-invasive, quick and easy to perform, claims the manufacturer. The measurement shows the patient’s response to treatment, enabling the correct prescription of medication and showing patient compliance. It also helps identify patients who do or do not require ongoing treatment. The monitor has a color touch screen and a battery indicator. It allows both adults and children to be tested.
Celia Sampol has been a journalist for more than 15 years. She worked in Brussels and Washington for national medias (Agence France Presse, Liberation, Europolitics). She's the editor-in-chief of NauticExpo e-magazine and MedicalExpo e-magazine.